Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer

被引:145
作者
Huang, HJ
Neven, P
Drijkoningen, M
Paridaens, R
Wildiers, H
Van Limbergen, E
Berteloot, P
Amant, F
Vergote, I
Christiaens, MR
机构
[1] Katholieke Univ Leuven Hosp, Dept Obstet & Gynaecol, Div Gynaecol Oncol, B-3000 Louvain, Belgium
[2] Chang Gung Mem Hosp, Dept Obstet & Gynaecol, Div Gynaecol Oncol, Taoyuan 333, Taiwan
[3] Katholieke Univ Leuven Hosp, Multidisciplinary Breast Ctr, B-3000 Louvain, Belgium
[4] Katholieke Univ Leuven Hosp, Dept Pathol, B-3000 Louvain, Belgium
[5] Katholieke Univ Leuven Hosp, Dept Med Oncol, B-3000 Louvain, Belgium
[6] Katholieke Univ Leuven Hosp, Dept Radiotherapy, B-3000 Louvain, Belgium
[7] Katholieke Univ Leuven Hosp, Dept Surg, B-3000 Louvain, Belgium
关键词
D O I
10.1136/jcp.2004.022772
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Aims: To investigate the association between tumour characteristics and HER-2/ neu by immunohistochemistry in primary operable breast cancer. Methods: The association between HER-2/ neu and other clinicopathological factors was evaluated in 1362 consecutive patients with primary breast cancer treated between 2000 and July 2003 in one centre. Microscopic tumour size, tumour grade, lymph node status, patient's age, oestrogen receptor ( ER), progesterone receptor ( PR), and joint ER/PR status were evaluated, using the chi(2) test for univariate analysis and logistic regression for multivariate analysis. The hormone receptors and HER-2/ neu were studied immunohistochemically. Using the HER-2/ neu DAKO scoring system, scores of 0, 1+, or 2+ were defined as negative and 3+ as positive. Data for DAKO scores 2+/3+ versus 0/1+ are also presented. Results: Hormone receptor negative breast cancers were more often HER-2/ neu positive than hormone receptor positive cancers, both for ER (28.7% v 6.8%) and PR (19.9% v 5.9%). In multivariate analysis, both ER, PR, and tumour grade were independently associated with HER-2/ neu. In ER+ tumours, HER-2/ neu overexpression was significantly lower in PR+ than in PR- cases (11.5% v 5.4%). HER-2/ neu overexpression (2.7%) was lowest in the large subgroup of ER+ PR+ tumours with low tumour grade ( grade 1 - 2), comprising 46.1% of all patients. Conclusions: ER, PR, and tumour grade are independent predictors for HER-2/ neu overexpression in women with primary operable breast cancer. ER and PR are negatively associated with HER-2/ neu, whereas tumour grade is positively associated with HER-2/ neu. In women with ER+ tumours, PR status also affects the likelihood of HER-2/ neu expression.
引用
收藏
页码:611 / 616
页数:6
相关论文
共 37 条
[1]   THE PRODUCT OF THE HUMAN C-ERBB-2 GENE - A 185-KILODALTON GLYCOPROTEIN WITH TYROSINE KINASE-ACTIVITY [J].
AKIYAMA, T ;
SUDO, C ;
OGAWARA, H ;
TOYOSHIMA, K ;
YAMAMOTO, T .
SCIENCE, 1986, 232 (4758) :1644-1646
[2]   Tumor variants by hormone receptor expression in white patients with node-negative breast cancer from the surveillance, epidemiology, and end results database [J].
Anderson, WF ;
Chu, KC ;
Chatterjee, N ;
Brawley, O ;
Brinton, LA .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (01) :18-27
[3]  
ARTEAGA CL, 1994, CANCER RES, V54, P3758
[4]   Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases [J].
Bardou, VJ ;
Arpino, G ;
Elledge, RM ;
Osborne, CK ;
Clark, GM .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (10) :1973-1979
[5]   ESTROGEN-DEPENDENT, TAMOXIFEN-RESISTANT TUMORIGENIC GROWTH OF MCF-7 CELLS TRANSFECTED WITH HER2/NEU [J].
BENZ, CC ;
SCOTT, GK ;
SARUP, JC ;
JOHNSON, RM ;
TRIPATHY, D ;
CORONADO, E ;
SHEPARD, HM ;
OSBORNE, CK .
BREAST CANCER RESEARCH AND TREATMENT, 1992, 24 (02) :85-95
[6]   The combination of p53 mutation and neu/erbB-2 amplification is associated with poor survival in node-negative breast cancer [J].
Bull, SB ;
Ozcelik, H ;
Pinnaduwage, D ;
Blackstein, ME ;
Sutherland, DAJ ;
Pritchard, KI ;
Tzontcheva, AT ;
Sidlofsky, S ;
Hanna, WM ;
Qizilbash, AH ;
Tweeddale, ME ;
Fine, S ;
McCready, DR ;
Andrulis, IL .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (01) :86-96
[7]   c-erbB2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases [J].
Carlomagno, C ;
Perrone, F ;
Gallo, C ;
DeLaurentiis, M ;
Lauria, R ;
Morabito, A ;
Pettinato, G ;
Panico, L ;
DAntonio, A ;
Bianco, AR ;
DePlacido, S .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (10) :2702-2708
[8]   IMMUNOHISTOCHEMICAL ANALYSIS OF P53 AND HER-2/NEU PROTEINS IN HUMAN TUMORS [J].
CHANG, K ;
DING, I ;
KERN, FG ;
WILLINGHAM, MC .
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 1991, 39 (09) :1281-1287
[9]  
Dowsett M, 2003, BREAST CANCER RES TR, V82, pS7
[10]  
Elledge RM, 1998, CLIN CANCER RES, V4, P7